<DOC>
	<DOCNO>NCT00135694</DOCNO>
	<brief_summary>In order prevent organ rejection , patient receive liver transplant currently require life-long treatment immune system-suppressing medication prevent rejection transplant liver . However , medication cause long-term side effect , infection , kidney problem , diabetes , cancer . In patient infected hepatitis C virus ( HCV ) , medication may increase risk HCV infection transplant liver . The purpose study determine whether slow withdrawal immune system-suppressing medication safe two group subject : receive liver transplant due HCV , receive liver transplant due non-immune , non-viral cause liver failure . The study also look whether slow withdrawal help reduce long-term side effect immune system-suppressing medication decrease chance HCV infection new liver transplant patient HCV .</brief_summary>
	<brief_title>Gradual Withdrawal Immune System Suppressing Drugs Patients Receiving Liver Transplant</brief_title>
	<detailed_description>This prospective multicenter , open-label , randomized trial individual liver failure due hepatitis C nonimmune nonviral cause undergo liver transplantation receive immunosuppression calcineurin inhibitor corticosteroid . Corticosteroids taper 3 month transplantation calcineurin inhibitor continue . Participants regularly assess evidence allograft rejection . One year transplantation , participant eligible withdrawal randomly assign 4 1 ratio immunosuppression withdrawal maintenance . Participants assign withdrawal undergo schedule taper approximately 1 year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>1 . Male female 18 year age old . 2 . Necessity liver transplant . 3 . For female childbearing potential : negative pregnancy test study entry agreement use approve method birth control duration participation . 4 . Ability provide inform consent . 5 . Availability donor specimen ( ) . 6 . For individual hepatitis C infection , presence hepatitis genome blood . 1 . Previous transplant . 2 . Multiorgan split liver transplant right trisegment . 3 . Living donor transplant . 4 . Donor liver donor positive antibody hepatitis C. 5 . Donor liver nonheartbeating donor . 6 . Liver failure due autoimmune disease . 7 . Fulminant liver failure . 8 . Hepatitis B infection define presence HbSAg hepatitisC infection genome genome 1 . 9 . Stage III high hepatocellular cancer . 10 . History malignancy except hepatocellular cancer , adequately treat situ cervical carcinoma , adequately treat basal squamous cell carcinoma skin , cancer judge 5year risk recurrence le 10 % . 11 . Active systemic infection time transplantation . 12 . Clinically significant chronic renal disease . 13 . Clinically significant cardiovascular cerebrovascular disease . 14 . Infection human immunodeficiency virus . 15 . Any investigational drug receive within 6 week study entry investigational vaccine receive time . 16 . Hypersensitivity tacrolimus . 17 . Unwillingness inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hepatitis</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>liver</keyword>
	<keyword>liver disease</keyword>
	<keyword>liver transplant</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>transplant</keyword>
	<keyword>hepatic</keyword>
	<keyword>hepatic transplantation</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>rejection</keyword>
</DOC>